Liquidia Co. (NASDAQ:LQDA) CFO Sells $45,722.88 in Stock

Liquidia Co. (NASDAQ:LQDA) CFO Michael Kaseta sold 3,136 shares of the company’s stock in a transaction dated Friday, April 12th. The stock was sold at an average price of $14.58, for a total value of $45,722.88. Following the completion of the transaction, the chief financial officer now directly owns 315,045 shares in the company, valued at $4,593,356.10. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Michael Kaseta also recently made the following trade(s):

• On Monday, March 18th, Michael Kaseta sold 12,166 shares of Liquidia stock. The stock was sold at an average price of $15.82, for a total value of $192,466.12.

Liquidia Trading Up 1.2 %

NASDAQ:LQDA traded up $0.16 on Wednesday, hitting $13.74. The company’s stock had a trading volume of 426,187 shares, compared to its average volume of 943,607. The firm has a market capitalization of $1.04 billion, a P/E ratio of -11.45 and a beta of 0.16. Liquidia Co. has a one year low of $5.71 and a one year high of $16.99. The stock has a fifty day moving average of $14.77 and a two-hundred day moving average of $10.88.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Wednesday, March 13th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.19). The business had revenue of $4.53 million during the quarter, compared to analyst estimates of $5.29 million. Liquidia had a negative net margin of 448.89% and a negative return on equity of 132.16%. As a group, sell-side analysts anticipate that Liquidia Co. will post -1.01 EPS for the current year.

Institutional Investors Weigh In On Liquidia

A number of large investors have recently modified their holdings of LQDA. Citigroup Inc. acquired a new stake in shares of Liquidia in the 1st quarter valued at $592,000. BlackRock Inc. lifted its stake in shares of Liquidia by 0.4% in the 1st quarter. BlackRock Inc. now owns 846,385 shares of the company’s stock valued at $6,077,000 after acquiring an additional 3,042 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Liquidia by 56.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 74,307 shares of the company’s stock valued at $534,000 after acquiring an additional 26,908 shares during the last quarter. Vontobel Holding Ltd. bought a new position in shares of Liquidia in the 1st quarter valued at $86,000. Finally, Vanguard Group Inc. lifted its stake in shares of Liquidia by 2.9% in the 1st quarter. Vanguard Group Inc. now owns 1,659,082 shares of the company’s stock valued at $11,912,000 after acquiring an additional 47,161 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on LQDA shares. Bank of America upped their price target on Liquidia from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, December 21st. LADENBURG THALM/SH SH increased their target price on Liquidia from $15.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, December 21st. Needham & Company LLC restated a “buy” rating and set a $28.00 target price on shares of Liquidia in a research note on Wednesday, April 10th. Wedbush reiterated an “underperform” rating and issued a $3.00 price objective on shares of Liquidia in a research report on Thursday, December 21st. Finally, HC Wainwright raised their price objective on Liquidia from $16.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, March 14th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $21.00.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).